Immune drug aims to wipe out prostate cancer in new trial

NCT ID NCT06347705

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called 2141-V11, which helps the immune system find and kill prostate cancer cells. It is given as an injection into the tumor, either alone before surgery for intermediate-risk cancer or combined with hormone therapy for high-risk or early metastatic cancer. The goal is to see if this approach can completely eliminate cancer or leave only tiny traces. About 57 men will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All protocol activites)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
RECRUITING

Rockville Centre, New York, 11553, United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.